InveniAI Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, today announced that since the launch of its AlphaMeld™ platform in early 2018, it has seen rapid adoption and interest not only across BioPharma, but also adjacencies such as Consumer Healthcare, Public Health/Vaccines, and Animal Therapeutics.
InveniAI seeks to make AlphaMeld the go-to platform for all innovative industries. The platform operates in real-time and seamlessly melds human expertise with powerful and optimized machine learning algorithms to identify signals of emerging innovation. With the commercial launch of AlphaMeld™ in Q1 2018, InveniAI has formed partnerships with large Pharma, Specialty Pharma, Biotech, Consumer Healthcare, and has numerous collaborations in advanced negotiations.
Krishnan Nandabalan, Ph.D., President and CEO, InveniAI Corporation said, “Anticipating the future and eliminating uncertainties is critical in shaping business strategy and driving corporate decisions. As we see the digital re-invention of industries, AlphaMeld brings both power and scale to decision-making and plugs a critical gap by engaging both internal experts and machine learning algorithms to identify emerging signals of innovation. Our collaborators are able to make both confident and early decisions using real-time insights specific to their organization’s needs.”
InveniAI continues to push the boundaries of AI and ML in all areas impacting R&D and productivity in BioPharma and is actively exploring adjacencies in other sectors to maximize the application of AlphaMeld. Collaborations are typically multiyear SaaS (Software-as-a-Service) deals.